



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** January 28, 2011

**To:** Primary Clinical Research Associates

**From:** Jack Beranek  
Research Protocol Specialist

**Re:** N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

Attached is updated form for this protocol. Edits are as follows:

<b>CRF Title</b>	<b>Brief Description of Edit</b>
Evaluation/Treatment Form	<ul style="list-style-type: none"><li>Added "154=Metabolic/Laboratory" to both primary reason treatment held, and primary reason for dose adjustment for Temsirolimus.</li></ul>

If you have any questions, please feel free to contact me at 507/538-1424.

JB/dg  
Enclosure